Volume 23, Issue 5, Pages (May 2018)

Slides:



Advertisements
Similar presentations
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity Leticia Corrales, Laura Hix Glickman,
Advertisements

Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails  Frank A.W. Verreck, Elma.
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Volume 5, Issue 1, Pages (January 2009)
Volume 43, Issue 1, Pages (July 2015)
Volume 22, Issue 4, Pages e4 (October 2017)
CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults 
Volume 25, Issue 2, Pages (February 2017)
Local Inflammatory Cues Regulate Differentiation and Persistence of CD8+ Tissue- Resident Memory T Cells  Tessa Bergsbaken, Michael J. Bevan, Pamela J.
Volume 44, Issue 6, Pages (June 2016)
Frank Kirstein, PhD, Natalie E
Volume 16, Issue 7, Pages (August 2016)
IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection  Hannah K. Bayes, Neil D. Ritchie, Christopher Ward,
Volume 21, Issue 13, Pages (December 2017)
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Volume 25, Issue 11, Pages (November 2017)
Volume 14, Issue 4, Pages (February 2016)
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till.
miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation
Preventing Allograft Rejection by Targeting Immune Metabolism
Viral Infection Results in Massive CD8+ T Cell Expansion and Mortality in Vaccinated Perforin-Deficient Mice  Vladimir P Badovinac, Sara E Hamilton, John.
Lung Airway-Surveilling CXCR3hi Memory CD8+ T Cells Are Critical for Protection against Influenza A Virus  Bram Slütter, Lecia L. Pewe, Susan M. Kaech,
Frank Kirstein, PhD, Natalie E
Volume 25, Issue 5, Pages (May 2017)
Volume 24, Issue 2, Pages (February 2016)
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Recombinant Human Granulocyte Colony-Stimulating Factor Significantly Decreases the Expression of CXCR3 and CCR6 on T Cells and Preferentially Induces.
Protective Capacity of Memory CD8+ T Cells Is Dictated by Antigen Exposure History and Nature of the Infection  Jeffrey C. Nolz, John T. Harty  Immunity 
Volume 34, Issue 5, Pages (May 2011)
Volume 33, Issue 1, Pages (July 2010)
Volume 23, Issue 10, Pages (October 2015)
Volume 45, Issue 1, Pages (July 2016)
Volume 25, Issue 4, Pages (April 2017)
Volume 26, Issue 2, Pages (February 2018)
Volume 17, Issue 3, Pages (October 2016)
Saskia Hemmers, Alexander Y. Rudensky  Cell Reports 
PD-1 Dependent Exhaustion of CD8+ T Cells Drives Chronic Malaria
Nicholas van Panhuys, Frederick Klauschen, Ronald N. Germain  Immunity 
Volume 7, Issue 1, Pages (April 2014)
Molecular Therapy - Oncolytics
Volume 11, Issue 4, Pages (April 2012)
RSV peptide library screen for candidate CD4+ T cell epitopes.
Volume 25, Issue 1, Pages e4 (October 2018)
Katelyn T. Byrne, Robert H. Vonderheide  Cell Reports 
Volume 5, Issue 1, Pages (January 2009)
Volume 38, Issue 6, Pages (June 2013)
Volume 25, Issue 1, Pages (January 2017)
Volume 22, Issue 1, Pages (January 2014)
Volume 23, Issue 8, Pages (August 2016)
Volume 19, Issue 9, Pages (May 2017)
Cell-Intrinsic IL-27 and gp130 Cytokine Receptor Signaling Regulates Virus-Specific CD4+ T Cell Responses and Viral Control during Chronic Infection 
Volume 19, Issue 11, Pages (June 2017)
Volume 25, Issue 12, Pages e3 (December 2018)
Katelyn T. Byrne, Robert H. Vonderheide  Cell Reports 
Volume 21, Issue 1, Pages (January 2017)
Volume 12, Issue 2, Pages (July 2015)
Volume 16, Issue 12, Pages (September 2016)
MP cells can mediate resistance in infectious models that induce TH1-type immunity. MP cells can mediate resistance in infectious models that induce TH1-type.
Ag 85A–specific immune responses.
Volume 9, Issue 6, Pages (June 2011)
Volume 11, Issue 7, Pages (May 2015)
Volume 17, Issue 7, Pages (November 2016)
Volume 25, Issue 5, Pages (May 2017)
Volume 19, Issue 6, Pages (May 2017)
Molecular Therapy - Methods & Clinical Development
Figure 1. T-cell immunogenicity of HZ DNA vaccines in C57BL/6 mice
Sang Kyun Ahn, Vanessa Tran, Andrea Leung, Mark Ng, Ming Li, Jun Liu 
Volume 25, Issue 11, Pages e5 (December 2018)
Volume 22, Issue 1, Pages (January 2014)
Volume 25, Issue 2, Pages (February 2017)
Presentation transcript:

Volume 23, Issue 5, Pages 1435-1447 (May 2018) STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection  Erik Van Dis, Kimberly M. Sogi, Chris S. Rae, Kelsey E. Sivick, Natalie H. Surh, Meredith L. Leong, David B. Kanne, Ken Metchette, Justin J. Leong, Jacob R. Bruml, Vivian Chen, Kartoosh Heydari, Nathalie Cadieux, Tom Evans, Sarah M. McWhirter, Thomas W. Dubensky, Daniel A. Portnoy, Sarah A. Stanley  Cell Reports  Volume 23, Issue 5, Pages 1435-1447 (May 2018) DOI: 10.1016/j.celrep.2018.04.003 Copyright © 2018 The Author(s) Terms and Conditions

Cell Reports 2018 23, 1435-1447DOI: (10.1016/j.celrep.2018.04.003) Copyright © 2018 The Author(s) Terms and Conditions

Figure 1 RR-CDG-Adjuvanted Vaccine Protects Equivalently to BCG Vaccination and Induces T Cell Populations Known to Protect against M. tuberculosis Infection (A) Experimental timeline for vaccine experiments. Mice were vaccinated using the indicated schedule and challenged with ∼100 CFUs of M. tuberculosis strain Erdman. (B) IFN-γ ELISPOT from PBMCs harvested 7 days after the second boost with PBS, BCG, 5Ag/RR-CDG, or 5Ag and re-stimulated ex vivo with the indicated peptide pools. (C) IFN-γ ELISPOT from PBMCs harvested 7 days after each boost from mice vaccinated with 5Ag/RR-CDG and re-stimulated ex vivo using the indicated peptide pools or left unstimulated (UN). (B and C) Data are expressed as the mean (± SD) of 10 animals assayed in two pools of five. Two-way ANOVA with Tukey’s post hoc p values; ∗∗p < 0.002, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. (D and E) CFU counts from lungs of vaccinated mice (D) 4 weeks and (E) 12 weeks after challenge. Mann-Whitney t test p values; ∗p < 0.02; ∗∗p < 0.002. (F) ICS for percentage of CD4+ T cells in the lungs of mice that are CXCR3− KLRG1+ 4 weeks after challenge. (G) ICS for percentage of CD4+ T cells in the lungs of mice that are CXCR3+ KLRG1− 4 weeks after challenge. One-way ANOVA with Tukey’s post hoc p value; ∗∗p < 0.002. (D–G), data are expressed as mean (± SD), and each symbol represents an individual animal. Data are representative of experiments done at least in duplicate. Error bars represent SD. See also Figures S1–S4. Cell Reports 2018 23, 1435-1447DOI: (10.1016/j.celrep.2018.04.003) Copyright © 2018 The Author(s) Terms and Conditions

Figure 2 5Ag/RR-CDG Vaccine-Induced Protection Requires STING but Not Type I IFN Signaling (A) IFN-γ ELISPOT from PBMCs re-stimulated ex vivo with Ag85B and ESAT-6 peptide pools 7 days after the second boost. Data are expressed as the mean (± SD) of 10 animals assayed in two pools of five. (B) ICS for percentage of Ag85B-specific CD4+ T cells that produce IFN-γ 7 days after the second boost. Data are expressed as mean (± SD), and each symbol represents blood pooled from five animals. Two-way ANOVA with Tukey’s post hoc p values; ∗p < 0.05, ∗∗∗∗p < 0.0001. (C and D) CFU counts from lungs of vaccinated mice (C) 4 weeks and (D) 12 weeks after challenge. For CFU experiments, data are expressed as mean (± SD), and each symbol represents an individual animal. Mann-Whitney t test p values; ∗p < 0.05, ∗∗p < 0.002. Data are representative of experiments done in duplicate. Error bars represent SD. Cell Reports 2018 23, 1435-1447DOI: (10.1016/j.celrep.2018.04.003) Copyright © 2018 The Author(s) Terms and Conditions

Figure 3 s.c. Boosting of BCG with 5Ag/RR-CDG Does Not Enhance Protection from M. tuberculosis Challenge (A) Experimental timeline for BCG boosting experiments. Mice were vaccinated using the indicated schedule and challenged with ∼100 CFUs of M. tuberculosis strain Erdman. (B) IFN-γ ELISPOT from PBMCs re-stimulated ex vivo with Ag85B and ESAT-6 peptide pools 7 days after the second boost. Data are expressed as the mean (± SD) of 10 animals assayed in two pools of five. Two-way ANOVA with Tukey’s post hoc p values; ∗∗∗∗p < 0.0001. (C and D) CFU counts from lungs of vaccinated mice (C) 4 weeks and (D) 12 weeks after challenge. For CFU experiments, data are expressed as mean (± SD), and each symbol represents an individual animal. Mann-Whitney t test p value; ∗∗p < 0.002. Data are representative of experiments done in duplicate. Error bars represent SD. Cell Reports 2018 23, 1435-1447DOI: (10.1016/j.celrep.2018.04.003) Copyright © 2018 The Author(s) Terms and Conditions

Figure 4 i.n. Administration of 5Ag/RR-CDG Induces Th17 Cells and Enhances Protection When Used as a Booster Vaccine for BCG (A and B) ICS for percentage of Ag85B-specific CD4+ T cells that produce (A) IFN-γ or (B) IL-17 7 days after the second boost. Data are expressed as the mean (± SD) of 10 animals assayed in two pools of five. One-way ANOVA with Tukey’s post hoc p values; ∗p < 0.05, ∗∗∗∗p < 0.0001. (C and D) CFU counts from lungs of vaccinated mice (C) 4 weeks and (D) 12 weeks after challenge. Mann-Whitney t test p values; ∗p < 0.05, ∗∗p < 0.002, ∗∗∗p < 0.0002, ∗∗∗∗p < 0.0001. (E and F) ICS for percentage of antigen-specific CD4+ T cells from the lungs of infected mice that produce (E) IFN-γ or (F) IL-17 upon re-stimulation ex vivo with Ag85B or ESAT-6 peptide pools 4 weeks after challenge. Two-way ANOVA with Tukey’s post hoc p values; ∗p < 0.05, ∗∗∗∗p < 0.0001. (C–F) Data are expressed as mean (± SD), and each symbol represents an individual animal. Data are representative of experiments done in duplicate. Error bars represent SD. See also Figure S5. Cell Reports 2018 23, 1435-1447DOI: (10.1016/j.celrep.2018.04.003) Copyright © 2018 The Author(s) Terms and Conditions

Figure 5 ML-RR-cGAMP-Adjuvanted Vaccine Elicits a Th17 Response and Protects against Challenge with M. tuberculosis (A) Representative flow plots showing log10 fluorescence and percentage of Ag85B-specific CD4+ T cells that produce IFN-γ, IL-17, or both 7 days after the first boost. (B and C) ICS for percentage of Ag85B-specific CD4+ T cells that produce (B) IFN-γ or (C) IL-17 7 days after the first boost. Data are expressed as mean (± SD) of five mice per group. Two-way ANOVA with Tukey’s post hoc p values; ∗p < 0.05, ∗∗p < 0.002, ∗∗∗∗p < 0.0001. (D) CFU counts from lungs of vaccinated mice 4 weeks after challenge. Data are expressed as mean (± SD), and each symbol represents an individual animal. Mann-Whitney t test p values; ∗p < 0.05, ∗∗p < 0.002. Data are representative of experiments done in duplicate. Error bars represent SD. Cell Reports 2018 23, 1435-1447DOI: (10.1016/j.celrep.2018.04.003) Copyright © 2018 The Author(s) Terms and Conditions